HCA Healthcare UK has opened a £26m specialist complex haematology and oncology unit at University College Hospital (UCH).
The investment, part of HCA UK’s longstanding partnership with University College Hospital, sees the transfer and expansion of inpatient capability into a specially designed 43-bed unit in the new Grafton Way building.
The unit provides cancer therapies including CAR-T Cell therapy, TIL therapy and haematopoietic stem cell transplants.
The expansion of HCA will also enable access to inpatient clinical trials delivered by the provider’s research arm, Sarah Canon Research Institute UK.
The new unit’s features include:
- An eight-bed advanced cellular therapy unit.
- A haematopoietic stem cell transplant unit for bone marrow transplants.
- Inpatient rooms with positive pressure lobbies to minimise the risk of infection for immunocompromised patients.
- Direct access to a 10-bed haematology oncology specialist consultant led Intensive Treatment Unit (ITU) for patients with complex needs.
- A dedicated isolation unit meaning patients with transmissible infections can continue to be cared for within the unit safely.
Day care and outpatient services for private patients will continue to be delivered at the UCH Macmillan Cancer Centre.
Claire Smith, CEO of HCA UK NHS Joint Ventures, said: “I am delighted to be expanding our inpatient care at HCA UK at UCH, further enhancing our capability and capacity to provide high quality cancer care and leading-edge treatments.”
